Rehovot, Israel – January 5st, 2009 – Dermipsor Ltd, Patricia Nasshorn joins Dermipsor as Business Development Consultant.

Patricia Nasshorn has been affiliated with Care Capital since 2002, providing business development support to a variety of portfolio companies, co-founding and heading business development for Vanda Pharmaceuticals, and seeking Phase III financing and royalty acquisition opportunities for Clinical Development Capital.  Her current focus, as Executive in Residence, is on business development consulting, for both portfolio and non-portfolio companies. In a variety of transaction-based assignments, Pat successfully closed over a dozen licensing agreements with pharmaceutical companies including:  Abbott, AZ, BDSI, BMS, GSK, Meda, Merck, Novartis, Salix, UCB and Wyeth.

Previously, Pat was President of Unipath Diagnostics, a $100 million women’s heath division of Unilever that was later sold to Inverness Medical in 2001. For the first twenty years of her career, from 1977 to 1997, she held a broad range of progressive positions beginning in pharmaceutical sales, marketing, strategic planning, business development and licensing, and general management, with Johnson & Johnson, Merck and Bristol-Myers Squibb.

Pat holds an MBA in Marketing and Finance, as well as a bachelor’s degree in Business Administration from Temple University, Philadelphia, PA.

CONTACT:
Zeev Even-Chen, Chief Executive Officer, Dermipsor 972-52-5287768
evenchen@actcom.co.il